mt DNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease
Adult
Male
0301 basic medicine
Medicine (General)
Mitochondrial Diseases
mtDNA copy number
DNA Copy Number Variations
DNA Mutational Analysis
QH426-470
DNA, Mitochondrial
03 medical and health sciences
R5-920
Sex Factors
Genetics
Humans
Muscle, Skeletal
Research Articles
Aged
mtDNA heteroplasmy
Age Factors
Middle Aged
6. Clean water
3. Good health
mitochondrial disease
Genes, Mitochondrial
m.3243A>G
MELAS
Mutation
Disease Progression
Linear Models
Regression Analysis
Female
DOI:
10.15252/emmm.201708262
Publication Date:
2018-05-07T11:15:17Z
AUTHORS (14)
ABSTRACT
Mitochondrial disease associated with the pathogenic m.3243A>G variant is a common, clinically heterogeneous, neurogenetic disorder. Using multiple linear regression and linear mixed modelling, we evaluated which commonly assayed tissue (blood N = 231, urine N = 235, skeletal muscle N = 77) represents the m.3243A>G mutation load and mitochondrial DNA (mtDNA) copy number most strongly associated with disease burden and progression. m.3243A>G levels are correlated in blood, muscle and urine (R2 = 0.61-0.73). Blood heteroplasmy declines by ~2.3%/year; we have extended previously published methodology to adjust for age. In urine, males have higher mtDNA copy number and ~20% higher m.3243A>G mutation load; we present formulas to adjust for this. Blood is the most highly correlated mutation measure for disease burden and progression in m.3243A>G-harbouring individuals; increasing age and heteroplasmy contribute (R2 = 0.27, P < 0.001). In muscle, heteroplasmy, age and mtDNA copy number explain a higher proportion of variability in disease burden (R2 = 0.40, P < 0.001), although activity level and disease severity are likely to affect copy number. Whilst our data indicate that age-corrected blood m.3243A>G heteroplasmy is the most convenient and reliable measure for routine clinical assessment, additional factors such as mtDNA copy number may also influence disease severity.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (235)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....